Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - CDK - Cdc7-IN-7

Cdc7-IN-7

CAS No. 1402059-17-9

Cdc7-IN-7( —— )

Catalog No. M32832 CAS No. 1402059-17-9

Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 169 In Stock
5MG 153 In Stock
10MG 224 In Stock
25MG 375 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Cdc7-IN-7
  • Note
    Research use only, not for human use.
  • Brief Description
    Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
  • Description
    Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1402059-17-9
  • Formula Weight
    410.42
  • Molecular Formula
    C21H22N4O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(OCC1CC1)(=O)C2=C(NN3CCOCC3)OC(=CC=4C=5C(NC4)=NC=CC5)C2=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • CDK4/6/1 Inhibitor

    CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).

  • CDK1-IN-2

    CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.

  • Senexin C

    Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cells.

Sign In Join Free